Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonardo Fabbri

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
European Journal of Clinical Investigation|November 10, 2015
Chronic critical illness: the price of survivalAlessandro Marchioni, Riccardo Fantini, Federico Antenora, et al.
Respiratory Research|June 27, 2012
Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trialAlberto Papi, Gabriele Nicolini, Nunzio Crimi, et al.
Pulmonary Pharmacology & Therapeutics|May 9, 2015
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation)Fulvio Braido, Giovanni Melioli, Mario Cazzola, et al.
COPD|September 26, 2006
Editorial: the Journal of COPD--new directions in disease understanding and managementJames D Crapo, Peter J Barnes, Leonardo Fabbri, et al.
The European Respiratory Journal|September 14, 2018
Inhaled corticosteroid containing combinations and mortality in COPDJørgen Vestbo, Leonardo Fabbri, Alberto Papi, et al.
Expert Review of Respiratory Medicine|December 16, 2017
Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary diseasePaola Rogliani, Vito Brusasco, Leonardo Fabbri, et al.
American Journal of Respiratory and Critical Care Medicine|March 26, 2005
Allergic rhinitis, asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004Leonardo Fabbri, Stephen P Peters, Ian Pavord, et al.
Respiratory Medicine|January 22, 2013
Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trialFernando J Martinez, Joseph Boscia, Gregory Feldman, et al.
Lancet (London, England)|February 13, 2018
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialAlberto Papi, Jørgen Vestbo, Leonardo Fabbri, et al.
American Journal of Respiratory and Critical Care Medicine|August 1, 2022
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its RevisionBartolome Celli, Leonardo Fabbri, Gerard Criner, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
European Journal of Clinical Investigation|November 10, 2015
Chronic critical illness: the price of survivalAlessandro Marchioni, Riccardo Fantini, Federico Antenora, et al.
Respiratory Research|June 27, 2012
Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trialAlberto Papi, Gabriele Nicolini, Nunzio Crimi, et al.
Pulmonary Pharmacology & Therapeutics|May 9, 2015
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation)Fulvio Braido, Giovanni Melioli, Mario Cazzola, et al.
COPD|September 26, 2006
Editorial: the Journal of COPD--new directions in disease understanding and managementJames D Crapo, Peter J Barnes, Leonardo Fabbri, et al.
The European Respiratory Journal|September 14, 2018
Inhaled corticosteroid containing combinations and mortality in COPDJørgen Vestbo, Leonardo Fabbri, Alberto Papi, et al.
Expert Review of Respiratory Medicine|December 16, 2017
Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary diseasePaola Rogliani, Vito Brusasco, Leonardo Fabbri, et al.
American Journal of Respiratory and Critical Care Medicine|March 26, 2005
Allergic rhinitis, asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004Leonardo Fabbri, Stephen P Peters, Ian Pavord, et al.
Respiratory Medicine|January 22, 2013
Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trialFernando J Martinez, Joseph Boscia, Gregory Feldman, et al.
Lancet (London, England)|February 13, 2018
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialAlberto Papi, Jørgen Vestbo, Leonardo Fabbri, et al.
American Journal of Respiratory and Critical Care Medicine|August 1, 2022
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its RevisionBartolome Celli, Leonardo Fabbri, Gerard Criner, et al.
Pageof 3